ID: ALA2441431

Max Phase: Preclinical

Molecular Formula: C22H23N3O5

Molecular Weight: 409.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C1OCc2cc(CC(=O)N3CCN(CCc4ccc([N+](=O)[O-])cc4)CC3)ccc21

Standard InChI:  InChI=1S/C22H23N3O5/c26-21(14-17-3-6-20-18(13-17)15-30-22(20)27)24-11-9-23(10-12-24)8-7-16-1-4-19(5-2-16)25(28)29/h1-6,13H,7-12,14-15H2

Standard InChI Key:  OYNPHFRQUFYXCN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 409.44

Molecular Weight (Monoisotopic): 409.1638

AlogP: 2.19

#Rotatable Bonds: 6

Polar Surface Area: 92.99

Molecular Species: NEUTRAL

HBA: 6

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.82

CX Basic pKa: 6.80

CX LogP: 2.61

CX LogD: 2.51

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.41

Np Likeness Score: -0.93

References

1. Tang H, de Jesus RK, Walsh SP, Zhu Y, Yan Y, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, Pai LY, Hampton C, Hernandez M, Owens K, Roy S, Kaczorowski GJ, Yang L, Garcia ML, Pasternak A..  (2013)  Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.,  23  (21): [PMID:24075732] [10.1016/j.bmcl.2013.08.104]

Source

Source(1):

• Scientific Literature